Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients

Speeckaert, Reinhart; Vermaelen, Karim; Geel, Nanja van; Autier, Philippe; Lambert, Jo; Haspeslagh, Marc; Gele, Mireille Van; Thielemans, Kris; Neyns, Bart; Roche, Nathalie; Verbeke, Natacha; Deron, Philippe; Speeckaert, Marijn M.; Brochez, Liève

doi:10.1016/j.ejca.2011.09.007

Cited by 94 publications

(79 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have shown that IDO1 þ cells were enriched in melanoma-draining lymph nodes (18,(21)(22)(23). Some studies also reported a correlation between high IDO1 expression in TDLN and poor clinical outcome of melanoma, suggesting that IDO1 contributes to immune evasion (22)(23)(24). However, another study performed in breast cancer did not show an enrichment of IDO1 þ cells in TDLN (25).…”

Section: Introductionmentioning

confidence: 81%

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

Théate

Baren

Pilotte

et al. 2015

Cancer Immunology Research

308

295

View full text Add to dashboard Cite

Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tumoral resistance to immune rejection. In humans, constitutive expression of IDO1 has been observed in several tumor types. However, a comprehensive analysis of its expression in normal and tumor tissues is still required to anticipate the risks and potential benefits of IDO1 inhibitors. Using a newly validated monoclonal antibody to human IDO1, we performed an extensive immunohistochemical analysis of IDO1 expression in normal and tumor tissues. In normal tissues, IDO1 was expressed by endothelial cells in the placenta and lung and by epithelial cells in the female genital tract. In lymphoid tissues, IDO1 was expressed in mature dendritic cells with a phenotype (CD83 þ ,

show abstract

Section: Introductionmentioning

confidence: 81%

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

Théate

Baren

Pilotte

et al. 2015

Cancer Immunology Research

308

295

View full text Add to dashboard Cite

show abstract

“…Enhanced IDO expression was independently associated with worse OS (p = 0.01) and disease-free survival (p = 0.015) of the patients. Again, the observed correlations were significant in non-metastatic lymph nodes as well [15]. Lee et al observed elevated IDO expression in 69% of melanomas of the skin and a significantly more frequent presence of IDO-positive lymph nodes in melanoma compared to a control group of lymph nodes from breast cancer patients [16].…”

Section: Discussionmentioning

confidence: 86%

The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma

Pelak¹,

Śnietura²,

Lange³

et al. 2015

pjp

View full text Add to dashboard Cite

We analyzed the prognostic significance of indoleamine-2,3-dioxygenase (IDO) and type 1 receptors for transforming growth factor beta (TGF-βR1) and interferon gamma (IFN-γR1) in resected nodal metastases of 48 malignant melanoma patients. In 32 cases the corresponding skin tumors were available. We used immunohistochemical (IHC) staining which was assessed by pathologists and by a computer-aided algorithm that yielded quantitative results, both absolute and relative. We correlated the results with the patient outcome. We identified absolute computer-assessed IDO levels as positively correlated with increased risk of death in a multivariate model (HR = 1.02; 95% CI: 1.002-1.04; p = 0.03). In univariate analysis, patients with IDO levels below the median had a better overall survival time (30.3 vs. 17.5 months; p = 0.03). TGF-βR1 and IFN-γR1 expression was modestly correlated (R = 0.34; p < 0.05) and TGF-βR1 expression was lower in lymph nodes than in matched primary skin tumors (Z = 2.87; p = 0.004). The pathologists' and computer-aided IHC assessment demonstrated high correlation levels (R = 0.61, R = 0.74 and R = 0.88 for IDO, TGF-βR1 and IFN-γR1, respectively). Indoleamine-2,3-dioxygenase is prognostic for the patient outcome in melanoma with nodal involvement and should be investigated prospectively for its predictive significance. IHC assessment by computer-aided methods is recommended as its gives IHC more objectivity and reproducibility.

show abstract

“…The prognostic significance of IDO immunoreactivity in addition to metastasis has also been shown in SLNs of 160 patients in all-site melanoma by Speeckaert et al [31]. These patients had a worse overall survival and progression free survival with high IDO expression [31]. IDO expression correlated with CTLA-4 expression in Tregs.…”

Section: Discussionmentioning

confidence: 87%

“…Knol et al [24] showed that Tregs decrease progression free survival in allsite metastatic melanoma. The prognostic significance of IDO immunoreactivity in addition to metastasis has also been shown in SLNs of 160 patients in all-site melanoma by Speeckaert et al [31]. These patients had a worse overall survival and progression free survival with high IDO expression [31].…”

Section: Discussionmentioning

confidence: 89%

FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients

Ryan

Crow

Kahmke

et al. 2014

American Journal of Otolaryngology

View full text Add to dashboard Cite

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients

Cited by 94 publications

References 28 publications

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma

FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients

Contact Info

Product

Resources

About